PEDIATRICS Vol. 59 No. 4 April 1977, pp. 505-512
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Modlin, J. F.
Right arrow Articles by Halsey, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Modlin, J. F.
Right arrow Articles by Halsey, N. A.

Epidemiologic Studies of Measles, Measles Vaccine, and Subacute Sclerosing Panencephalitis

John F. Modlin M.D.1, J. T. Jabbour M.D.1, John J. Witte M.D.1, and Neal A. Halsey M.D.1

1 Immunization Division, Bureau of State Services, and Field Services Division, Bureau of Epidemiology, Center for Disease Control, Atlanta, and the Section of Pediatric Neurology, Department of Neurology, University of Tennessee Center for the Health Sciences, Memphis

Histories obtained in 350 of 375 clinically confirmed cases of subacute sclerosing panencephalitis (SSPE) reported to a national registry showed that 292 patients had measles and 58 had no history of measles. Forty of the latter patients received live, attenuated measles virus vaccine. In patients with a history of measles, measles illness occurred before age 2 years in 46%, and a mean of 7.0 years before onset of SSPE. In contrast, there was no relationship of SSPE with age at vaccination in 35 of the 40 patients historically associated with measles vaccine, and SSPE occurred a mean of 3.3 years after vaccination.

Based on estimated national measles morbidity data and national measles vaccine distribution data, the risk of SSPE following measles vaccination (0.5 to 1.1 cases/106) appears to be less than the risk following measles (5.2 to 9.7 cases/106). Because live measles vaccine is highly effective in preventing measles illness and a high proportion of children in the United States have received measles vaccine, these data are consistent with the observed downward trend in SSPE incidence since 1969.

Submitted on May 20, 1976
Accepted on September 27, 1976




This article has been cited by other articles:


Home page
 Int J EpidemiolHome page
H Campbell, N Andrews, K E Brown, and E Miller
Review of the effect of measles vaccination on the epidemiology of SSPE
Int. J. Epidemiol., December 1, 2007; 36(6): 1334 - 1348.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. P. Owens, A. M. Ritchie, D. H. Gilden, M. P. Burgoon, D. Becker, and J. L. Bennett
Measles virus-specific plasma cells are prominent in subacute sclerosing panencephalitis CSF
Neurology, May 22, 2007; 68(21): 1815 - 1819.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
M. Ludlow, S. McQuaid, S. L. Cosby, R. Cattaneo, B. K. Rima, and W. P. Duprex
Measles virus superinfection immunity and receptor redistribution in persistently infected NT2 cells
J. Gen. Virol., August 1, 2005; 86(8): 2291 - 2303.
[Abstract] [Full Text] [PDF]